The use of groups of antidepresivos for treatment of premature ejaculation, such as: monoaminaoxidase inhibitors (MAOI); antidepressants atu00ecpicos; selective serotonin reuptake inhibitors (except fluoxetine)

摘要

The use of groups of antidepresivos for treatment of premature ejaculation. Such as: monoaminaoxidase inhibitors (MAOI); antidepressants atu00ecpicos; selective serotonin reuptake inhibitors (except fluoxetine). This patent relates to the chemical industry: pharmaceutical.The most common male sexual dysfunction that affects the man is premature ejaculation, both in our country and world level.The etiology of premature ejaculation, contrary to what was previously; this was due to anxiety, nervousness, fear of sexual performance; today it is known that it is due to the low concentration of serotonin (5HT) in the limbic hypothalamic synaptic clefts, with, in re Ceptores and subreceptores peripherals.On the level of the spinal cord and the clinical expression of male sexual dysfunction, called - premature ejaculation. To increase the concentration of serotonin in synaptic regions of the limbic system, hypothalamus, as well as in synapses of the spinal cord and other active sites occurs the clinical control of premature ejaculation.The use of groups of antidepresivos for treatment of premature ejaculation, such as: monoaminaoxidase inhibitors (MAOI); antidepressants atu00ecpicos; selective serotonin reuptake inhibitors (except fluoxetine). This patent claiming all medicines, mentioned above, for use in the treatment of premature ejaculation.The claim of the use of monoaminooxidade inhibitors (MAOI), modulators of response mediated by monoamines (adrenergic modulators), selective serotonin reuptake inhibitors (except fluoxetine).Inhibitors of recaptau00e7u00e2o of adrenaline and serotonin, is due to the fact that all products belonging to these groups, in a manner directly or indirectly, participate in the regulation of serotonin (5-HT) in various subtypes of receptors (5-HT) and, to a greater or lesser extent, Co Ntrole cum in man. We stress that fluoxetine. It is not part of our claim.Only the remaining other medicines. Of the various groups of antidepressants. Previously mentioned. So the request of this patent gives the characteristic of novelty, inventiveness and industrial applicability, according to the law of industrial property n 0 9279 / 96, as well as the Paris Convention for the protection of industrial property.